Entrada Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue | $875 | $20,558 |
| Operating expenses: | ||
| Research and development | 33,054 | 32,074 |
| General and administrative | 10,124 | 10,274 |
| Total operating expenses | 43,178 | 42,348 |
| Loss from operations | (42,303) | (21,790) |
| Other income: | ||
| Interest and other income | 2,624 | 4,441 |
| Total other income | 2,624 | 4,441 |
| Loss before provision for income taxes | (39,679) | (17,349) |
| Provision for income taxes | 38 | — |
| Net loss | $(39,717) | $(17,349) |
| Net loss per share, basic and diluted | $(0.95) | $(0.42) |
| Weighted‑average common shares outstanding, basic and diluted | 41,836,275 | 41,073,732 |
| Other comprehensive (loss) income: | ||
| Unrealized (loss) gain on marketable securities | (406) | 480 |
| Total other comprehensive (loss) gain | (406) | 480 |
| Total comprehensive loss | $(40,123) | $(16,869) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.